Every Form 4 that Cosmos Holdings Inc. (COSM) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow COSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COSM filings page.
Siokas Grigorios reported reported purchase transactions in this Form 4 filing.
Cosmos Health Inc. CEO and director Grigorios Siokas acquired 349,825 shares of common stock at $0.2001 per share pursuant to a Debt Exchange Agreement dated July 30, 2026, cancelling $70,000 of debt owed to him.
Following this transaction, he directly holds 14,597,917 shares of Cosmos Health common stock. The exchange rate equals the fair market value of the common stock on July 30, 2026, and the transaction was not indicated as being under a Rule 10b5-1 trading plan.
Cosmos Health Inc. reported that Chief Financial Officer Georgios Terzis acquired 328,407 shares of common stock at $0.1827 per share. Under a Debt Exchange Agreement dated July 29, 2026, these Exchange Shares were issued in exchange for $60,000 of debt the company owed to him, bringing his direct holdings to 2,563,805 shares.
Siokas Grigorios reported reported purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Executive Officer and 10% owner Grigorios Siokas acquired 766,284 shares of common stock at $0.1827 per share on July 29, 2026 under a Debt Exchange Agreement. He received these Exchange Shares in return for $140,000 of company debt owed to him, increasing his direct holdings to 14,248,092 shares.
Terzis Georgios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Financial Officer Georgios Terzis acquired 168,135 shares of common stock at $0.2498 per share through a debt-for-equity exchange. Under a Debt Exchange Agreement dated June 16, 2026, $42,000 of debt the company owed to him was converted into these shares.
Following this transaction, Terzis directly holds 2,235,398 Cosmos Health common shares. The transaction reflects an insider increasing his equity stake while eliminating a portion of the company’s outstanding debt obligation to him at the fair market value as of June 16, 2026.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. director and CEO Grigorios Siokas acquired additional common shares through a debt-for-equity exchange with the company. Under a Debt Exchange Agreement dated June 11, 2026, he received 218,447 shares of common stock at an Exchange Rate of $0.206 per share, equal to the fair market value on that date, in exchange for $45,000 of debt the company owed him. Following this transaction, he holds 13,481,808 common shares directly. This increases his equity stake while reducing a related-party debt obligation on the company’s balance sheet.
Siokas Grigorios reported open-market purchase transactions in this Form 4 filing.
Cosmos Health Inc. Chief Executive Officer Grigorios Siokas acquired 701,447 shares of common stock at $0.2281 per share. Instead of paying cash, the shares were received under a Debt Exchange Agreement dated June 10, 2026, in exchange for $160,000 of debt the company owed him.
Following this transaction, Mr. Siokas directly holds 13,263,361 shares of Cosmos Health common stock. The share price used in the exchange reflects the fair market value of the stock on June 10, 2026, as defined in the agreement.
Cosmos Health Inc. director Karkantzos Theodoros Christos received an award of 20,000 shares of Common Stock at $0.283 per share under the company’s 2024 & 2025 Omnibus Incentive Plan. A related Restricted Stock Unit grant converted, leaving him with 35,000 common shares held directly after these compensation transactions, and no remaining RSUs.
Cosmos Health Inc. director John James Hoidas received an award of 20,000 shares of common stock on May 19, 2026, converted from restricted stock units under the company’s 2024 & 2025 Omnibus Incentive Plan. The award was a compensation-related grant exempt under Rule 16b-3, bringing his direct holdings to 50,000 shares.
Cosmos Health Inc. director and secretary Demetrios G. Demetriades received an award of 20,000 shares of common stock at $0.283 per share as equity compensation. The grant came from the 2024 & 2025 Omnibus Incentive Plan, converting 20,000 vested RSUs into common shares and bringing his direct holdings to 55,000 shares.
Cosmos Health Inc. director Aslidis Anastasios received an award of 40,000 shares of Common Stock on May 19, 2026, granted under the company’s 2024 & 2025 Omnibus Incentive Plan as equity compensation exempt under Rule 16b-3.
The award reflects the vesting and conversion of an equal number of Restricted Stock Units into common shares at a stated value of $0.283 per share. After these transactions, Anastasios directly holds 100,000 shares of Common Stock. The filing shows no open‑market purchases or sales, only compensation-related acquisitions.
Cosmos Health Inc. director Suhel Bhutawala received an award of 20,000 shares of common stock valued at $0.283 per share on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan. These shares came from restricted stock units that vested immediately and were converted into common stock in transactions exempt under Rule 16b-3. Following the award and RSU conversion, Bhutawala directly holds 65,000 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Financial Officer Georgios Terzis reported equity compensation involving 850,000 shares. He received an award of 850,000 shares of Common Stock at $0.283 per share, granted on May 19, 2026 under the company’s 2024 & 2025 Omnibus Incentive Plan and exempt under Rule 16b-3.
On the same date, 850,000 Restricted Stock Units converted into an equal number of Common Stock shares, with the RSUs vesting immediately at grant and then being fully settled. Following these transactions, Terzis holds 2,067,263 Common Stock shares directly.
Cosmos Health Inc. Director and Chief Executive Officer Grigorios Siokas received an equity compensation award that converted restricted stock units into common shares. On May 19, 2026, 2,350,000 restricted stock units granted under the company’s 2024 & 2025 Omnibus Incentive Plan vested and were converted into 2,350,000 shares of common stock at a stated value of $0.283 per share.
Following this grant and conversion, Siokas directly owns 12,561,914 shares of Cosmos Health common stock. The filing notes that these transactions were made under the company’s omnibus incentive plan and are exempt under Rule 16b-3, indicating they are compensation-related awards rather than open-market purchases or sales.
Cosmos Health Inc. CEO, director and 10% owner Grigorios Siokas acquired 388,532 shares of common stock on February 12, 2026. The shares were issued at $0.3732 per share in exchange for $145,000 of debt the company owed to him. Following this transaction, he directly owns 8,861,914 shares of Cosmos Health common stock.
Cosmos Health Inc. Chief Executive Officer, director and 10% owner Grigorios Siokas acquired 291,262 shares of common stock on February 11, 2026. The shares were obtained at $0.4120 per share in exchange for $120,000 of debt the company owed to him under a debt exchange agreement.
Following this transaction, Mr. Siokas directly beneficially owns 8,473,382 shares of Cosmos Health common stock.
Cosmos Health Inc. filed a Form 4 showing that CEO, director and 10% owner Grigorios Siokas acquired additional common shares through a debt-for-equity exchange. On January 23, 2026, he obtained 90,325 shares of common stock at $0.4982 per share, representing the fair market value that day, in exchange for $45,000 of debt the company owed him under a Debt Exchange Agreement. Following this transaction, he directly holds 8,182,120 common shares.
Cosmos Health Inc.'s Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired additional common shares of the company through a debt exchange. On January 20, 2026, he obtained 353,321 shares of common stock at $0.4953 per share, described as the fair market value on that date. The shares were issued under a Debt Exchange Agreement in which $175,000 of debt the company owed to Mr. Siokas was exchanged for equity.
Following this transaction, Mr. Siokas beneficially owns 8,091,795 shares of Cosmos Health common stock in direct ownership. The filing characterizes the transaction with code "P" and notes that these shares are classified as Exchange Shares under the terms of the Debt Exchange Agreement.
Cosmos Health Inc.'s Chief Executive Officer, director and 10% owner Grigorios Siokas reported acquiring 493,495 shares of common stock on January 14, 2026. The shares were obtained at $0.4458 per share, described as the fair market value on that date, through a debt exchange agreement with the company.
Under this agreement, Mr. Siokas exchanged $220,000 of debt that the company owed him for these "Exchange Shares". Following the transaction, he beneficially owned 7,738,474 shares of Cosmos Health common stock in direct ownership.
Cosmos Health Inc. insider filing shows its CEO and 10% owner, Grigorios Siokas, acquiring 113,185 shares of common stock on January 12, 2026. The shares were obtained at $0.5036 per share under a Debt Exchange Agreement, using $57,000 of debt the company owed to him as payment instead of cash. After this transaction, he beneficially owns 7,244,979 common shares directly.
Cosmos Health Inc. insider transaction: Chief Executive Officer, director, and 10% owner Grigorios Siokas acquired 156,190 shares of Common Stock on January 8, 2026. The shares were obtained at $0.5186 per share pursuant to a Debt Exchange Agreement, in which $81,000 of debt that the company owed to Mr. Siokas was exchanged for stock at the fair market value on that date. Following this transaction, he beneficially owned 7,131,794 shares of Common Stock, held directly.
Cosmos Health Inc. director, chief executive officer, and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On January 7, 2026, he acquired 124,880 shares of common stock at $0.5205 per share, identified as Exchange Shares under a Debt Exchange Agreement with the company. The shares were issued in exchange for $65,000 of debt the company owed to him, effectively converting that obligation into equity rather than a cash payment. Following this transaction, he beneficially owned 6,975,604 shares of the company’s common stock, held directly.
Cosmos Health Inc. CEO Grigorios Siokas acquired 133,953 common shares at $0.5375 per share on January 6, 2026. The shares were issued under a Debt Exchange Agreement in which $72,000 of debt the company owed to Mr. Siokas was exchanged for stock at the fair market value of the common shares on that date.
After this transaction, Mr. Siokas beneficially owned 6,850,724 shares of Cosmos Health common stock in direct ownership. He is reported as a director, chief executive officer, and a 10% owner of the company.
Cosmos Health Inc. CEO Grigorios Siokas converted $70,000 of company debt into 168,472 shares of common stock on December 15, 2025. The shares, described as Exchange Shares under a Debt Exchange Agreement between Siokas and the company, were issued at $0.4155 per share, identified as the fair market value of the stock on that date.
After this transaction, Siokas directly beneficially owned 6,628,457 Cosmos Health common shares. He is listed as a director, chief executive officer, and a more than 10% owner of Cosmos Health Inc.
Cosmos Health Inc. (COSM) reported an insider transaction by Chief Executive Officer, director and 10% owner Grigorios Siokas. On 11/25/2025, Mr. Siokas acquired 55,732 shares of common stock at $0.628 per share through a debt-for-equity exchange.
Under a Debt Exchange Agreement between Mr. Siokas and the company, these Exchange Shares were issued in exchange for $35,000 of debt that Cosmos Health owed to him. Following this transaction, Mr. Siokas beneficially owns 6,383,625 shares of Cosmos Health common stock, held in direct ownership.
Cosmos Health Inc. (COSM) CEO, director and 10% owner Grigorios Siokas reported acquiring common stock through a debt-for-equity exchange. On 11/21/2025, he acquired 56,080 shares of common stock at $0.6776 per share, identified as Exchange Shares under a Debt Exchange Agreement between him and the company. The price reflects the fair market value of the stock on that date and was used to exchange $38,000 of debt the company owed to him. Following this transaction, he beneficially owned 6,327,893 shares of Cosmos Health common stock, held directly.
Cosmos Health Inc. (COSM) insider Grigorios Siokas increased his stake through a debt-for-equity exchange. On 11/20/2025, the CEO, director and 10% owner acquired 51,315 shares of common stock at $0.6236 per share. The shares were issued as "Exchange Shares" in satisfaction of $32,000 that the company owed to him under a debt exchange agreement, using the fair market value of the stock on that date.
After this transaction, Siokas beneficially owned 6,271,813 shares held directly. This was a non-cash transaction for the company, converting a payable to equity while increasing the CEO’s direct ownership.
Cosmos Health Inc. (COSM) disclosed that its Chief Executive Officer, director and 10% owner, Grigorios Siokas, acquired additional common shares through a debt-for-equity exchange. On November 19, 2025, he acquired 61,614 shares of common stock at $0.6492 per share, described as the fair market value of the stock on that date. The shares were issued in exchange for a total of $40,000 that the company owed to Mr. Siokas under a debt exchange agreement. Following this transaction, he beneficially owns 6,220,498 common shares directly.